ES2155436T3 - Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas. - Google Patents

Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas.

Info

Publication number
ES2155436T3
ES2155436T3 ES92101272T ES92101272T ES2155436T3 ES 2155436 T3 ES2155436 T3 ES 2155436T3 ES 92101272 T ES92101272 T ES 92101272T ES 92101272 T ES92101272 T ES 92101272T ES 2155436 T3 ES2155436 T3 ES 2155436T3
Authority
ES
Spain
Prior art keywords
immunological
hbeag
vaccines
hepatitis
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92101272T
Other languages
English (en)
Inventor
Michael Noah
Michael Broker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2155436T3 publication Critical patent/ES2155436T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/94—Saccharomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBEN VECTORES DE EXPRESION DE LEVADURAS RECOMBINANTES CON LAS CARACTERISTICAS INDICADAS EN LAS REIVINDICACIONES DE PATENTE. ESTOS VECTORES DE EXPRESION DE LEVADURAS RECOMBINANTES SE PUEDEN UTILIZAR PARA LA PRODUCCION DE HBEAG EN ORGANISMOS HUESPEDES DE LA LEVADURA. ADEMAS, SE DESCRIBEN LOS CORRESPONDIENTES SISTEMAS DE EXPRESION, ORGANISMOS HUESPEDES TRANSFORMADOS, DIAGNOSTICOS Y MEDICAMENTOS.
ES92101272T 1991-03-09 1992-01-27 Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas. Expired - Lifetime ES2155436T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4107612A DE4107612A1 (de) 1991-03-09 1991-03-09 Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen

Publications (1)

Publication Number Publication Date
ES2155436T3 true ES2155436T3 (es) 2001-05-16

Family

ID=6426883

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92101272T Expired - Lifetime ES2155436T3 (es) 1991-03-09 1992-01-27 Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas.

Country Status (10)

Country Link
US (1) US6277631B1 (es)
EP (1) EP0503252B1 (es)
JP (1) JP3329848B2 (es)
AU (1) AU664982B2 (es)
CA (1) CA2062410A1 (es)
DE (2) DE4107612A1 (es)
DK (1) DK0503252T3 (es)
ES (1) ES2155436T3 (es)
GR (1) GR3036125T3 (es)
PT (1) PT503252E (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3847257B2 (ja) * 2000-08-11 2006-11-22 株式会社先端生命科学研究所 Ｈｂｖの検出又は測定方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
AU8746582A (en) 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1988006185A1 (en) * 1987-02-11 1988-08-25 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
FR2635115B1 (fr) * 1988-08-05 1992-04-03 Rhone Poulenc Sante Procede de preparation de la serum albumine humaine a partir d'une levure
CA2009270A1 (en) * 1989-02-06 1990-08-06 Daniel J. Hicklin Stabilized hepatitis e antigen suitable for immunoassays
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases

Also Published As

Publication number Publication date
EP0503252A2 (de) 1992-09-16
PT503252E (pt) 2001-09-28
US6277631B1 (en) 2001-08-21
GR3036125T3 (en) 2001-09-28
DE59209899D1 (de) 2001-05-10
DK0503252T3 (da) 2001-07-02
EP0503252B1 (de) 2001-04-04
JPH07203971A (ja) 1995-08-08
AU1146692A (en) 1992-09-10
JP3329848B2 (ja) 2002-09-30
AU664982B2 (en) 1995-12-14
EP0503252A3 (en) 1992-12-09
CA2062410A1 (en) 1992-09-10
DE4107612A1 (de) 1992-09-10

Similar Documents

Publication Publication Date Title
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DK66692A (da) En mammal cytokin, il-11
ATE198754T1 (de) Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
DE3786592D1 (de) Transformation von trichoderma.
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DK0541692T3 (da) Herpes simplex virus VP-16-vacciner
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
DE3061854D1 (en) Process for the preparation of interferon and culture medium composition used in it
AU7784687A (en) Polypeptides useful in diagnosis of mycoplasma infections in swine and recombinant-dna methods for manufacturing same
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
AU2567888A (en) Hiv peptides and methods for detection of hiv
ATE119203T1 (de) Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.
ES2056075T3 (es) Anticuerpos monoclonales para regiones especificas antigenicas del virus de inmunodeficiencia humana y procedimientos para su uso.
FR2355505A1 (fr) Nouvel agent adjuvant immunitaire
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
IT1241003B (it) Procedimento per la purificazione di un polipeptide ricombinante hdag equivalente, polipeptide hdag equivalente e saggi immunologici che lo utilizzano
FI870501L (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
KR920002631A (ko) 면역학적 캐리어 및 강화 특성을 지닌 나이세리아 메닌자이티디스 외막의 클래스 ⅱ 단백질
SU681928A1 (ru) Адъювант

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 503252

Country of ref document: ES